Equity Overview
Price & Market Data
Price: $10.40
Daily Change: +$0.78 / 7.50%
Range: $9.21 - $10.58
Market Cap: $1,519,693,440
Volume: 3,933,546
Performance Metrics
1 Week: 1.56%
1 Month: 26.95%
3 Months: 22.90%
6 Months: 30.12%
1 Year: 19.93%
YTD: 33.12%
Company Details
Employees: 93
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. The company was founded in 2018 and is headquartered in San Francisco, California.